CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $126.14M, lower than 95% of all stocks globally
- PositionGross margin is 100%, higher than 95% of its Biotechnology peers (median 67.1%)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
179.77BKRW126.14M · vs all stocks (USD)
Revenue (TTM)
9.78BKRW6.86M · vs all stocks (USD)
Profit Margin
-60.99%vs Biotechnology peers
52-Week Change
-16.64%vs all stocks
Market Capitalization
179.77BKRW126.14M · vs all stocks (USD)
Enterprise Value
155.92BKRW109.40M · vs all stocks (USD)
Forward P/E
30.93xvs Biotechnology peers
Price to Sales (TTM)
18.63xvs Biotechnology peers
Price to Book (MRQ)
8.00xvs Biotechnology peers
Enterprise to Revenue
15.94xvs Biotechnology peers
Enterprise to EBITDA
-30.36xvs Biotechnology peers
Gross Margin
100.00%vs Biotechnology peers
Profit Margin
-60.99%vs Biotechnology peers
Operating Margin
-39.28%vs Biotechnology peers
Return on Assets (TTM)
-18.24%vs Biotechnology peers
Return on Equity (TTM)
-22.93%vs Biotechnology peers
Revenue (TTM)
9.78BKRW6.86M · vs all stocks (USD)
Revenue per Share (TTM)
312.38KRWUpdated Jul 15, 2026Quarterly Revenue Growth
102.50%vs Biotechnology peers
Gross Profit (TTM)
9.78BKRW6.86M · vs all stocks (USD)
EBITDA (TTM)
-5.14BKRW-3.60M · vs all stocks (USD)
Net Income (TTM)
-5.97BKRW-4.19M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
71.80%vs Biotechnology peers
Operating Cash Flow (TTM)
-4.00BKRW-2.81M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-5.41BKRW-3.80M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
11.71BKRWFY2025 · Dec 31, 2025Gross Profit
11.71BKRWFY2025 · Dec 31, 2025Operating Income
-5.89BKRW-4.13M · vs all stocks (USD)
Pre-tax Income
-5.41BKRWFY2025 · Dec 31, 2025Net Income
-5.41BKRWFY2025 · Dec 31, 2025EBIT
-5.21BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-3.28BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
7.86BKRWFY2025 · Dec 31, 2025Other Operating Expenses
-13.47MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
449.71MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
203.28MKRWFY2025 · Dec 31, 2025EPS (Basic)
-171.00KRWFY2025 · Dec 31, 2025EPS (Diluted)
-171.00KRWFY2025 · Dec 31, 2025Basic Shares Outstanding
31.65MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
31.65MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-5.41BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-6.25BKRWFY2025 · Dec 31, 2025Free Cash Flow
-8.54BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
8.14BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-5.41BKRWFY2025 · Dec 31, 2025Stock-based Compensation
274.35MKRWFY2025 · Dec 31, 2025Other Non-cash Items
-246.43MKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-761.60MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-102.14MKRWFY2025 · Dec 31, 2025Capital Expenditures
-2.29BKRWFY2025 · Dec 31, 2025Purchase of Investments
-21.80BKRWFY2025 · Dec 31, 2025Sale of Investments
24.49BKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
394.16MKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
226.83MKRWFY2025 · Dec 31, 2025Shares Outstanding
31.76MSharesUpdated Jul 15, 2026Float Shares
21.39MSharesUpdated Jul 15, 2026% Held by Insiders
24.52%vs all stocks
% Held by Institutions
5.81%vs all stocks
Total Cash (MRQ)
19.82BKRW13.90M · vs all stocks (USD)
Total Cash per Share (MRQ)
624.69KRWUpdated Jul 15, 2026Total Debt (MRQ)
3.49BKRW2.45M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1445xvs Biotechnology peers
Current Ratio (MRQ)
5.27xvs Biotechnology peers
Book Value per Share (MRQ)
707.43KRWUpdated Jul 15, 2026Total Assets
29.67BKRW20.82M · vs all stocks (USD)
Total Current Assets
20.92BKRWFY2025 · Dec 31, 2025Total Liabilities
6.07BKRWFY2025 · Dec 31, 2025Total Non-current Assets
8.75BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
2.71BKRWFY2025 · Dec 31, 2025Total Current Liabilities
3.36BKRWFY2025 · Dec 31, 2025Cash
3.12BKRWFY2025 · Dec 31, 2025Cash Equivalents
5.02BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
8.14BKRWFY2025 · Dec 31, 2025Other Short-term Investments
10.00BKRWFY2025 · Dec 31, 2025Accounts Receivable
279.57MKRWFY2025 · Dec 31, 2025Inventory
340.59MKRWFY2025 · Dec 31, 2025Accounts Payable
405.40MKRWFY2025 · Dec 31, 2025Short-term Debt
870.54MKRWFY2025 · Dec 31, 2025Other Current Liabilities
-160.00KRWFY2025 · Dec 31, 2025Long-term Debt
2.49BKRWFY2025 · Dec 31, 2025Common Stock (Book)
3.18BKRWFY2025 · Dec 31, 2025Retained Earnings
-101.62BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
23.60BKRW16.56M · vs all stocks (USD)
52-Week Low
5.31KKRWUpdated Jul 15, 202652-Week High
20.10KKRWUpdated Jul 15, 202652-Week Change
-16.64%vs all stocks
50-Day MA
8.35KKRWUpdated Jul 15, 2026200-Day MA
11.81KKRWUpdated Jul 15, 2026Avg 10-Day Volume
153.50KSharesUpdated Jul 15, 2026Avg 30-Day Volume
210.13KSharesUpdated Jul 15, 2026Diluted EPS (TTM)
-171.00KRWUpdated Jul 15, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 100%, higher than 95% of its Biotechnology peers (median 67.1%)Significant
Gross margin: 1.00Industry median: 0.67Industry P95: 1.00Peers compared: 261
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 1.00Profit Margin: -0.61
Financial Health
Altman Z-Score 13.49: safe zoneNotable
Altman Z-Score: 13.49
High structural barrier to entryNotable
Barrier to Entry: 82.88
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $126.14M, lower than 95% of all stocks globallySignificant
Market cap (USD): 126,137,386.036Global P5: 269,387,740.27
Revenue is $6.86M, lower than 95% of all stocks globallySignificant
Revenue (USD): 6,864,958.453Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
CVRx, Inc.
Tier 1ProductionApproval-Gated PipelineRule
PepGen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pyridam Farma Tbk.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cellbion Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Curacle Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Scancell Holdings Plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Nibec Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Polaryx Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Engene Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRule
Faron Pharmaceuticals Oy
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Emtek Shenzhen Co., Ltd.
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedIndustry-Benchmarked ROA and Margin Elevated
Xi'an Sinofuse Electric Co., Ltd.
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedIndustry-Benchmarked ROA and Margin Elevated
Guangdong Lvtong New Energy Technology Co., Ltd.
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedIndustry-Benchmarked ROA and Margin Elevated